港股異動 | 金蝶國際(0268.HK)一度漲7%破頂 年內股價升近4倍
格隆匯11月30日丨金蝶國際(0268.HK)盤中快速拉昇至7%,盤中高見27.8港元創新高價,年內股價升近4倍。暫成交1.59億港元,總市值939.3億港元。金蝶賬無憂憑藉其推出的“智慧代賬”財税行業雲解決方案在財税服務SaaS領域的突出實踐與貢獻,日前榮獲“年度最佳數字化解決方案”。另外,金蝶宣佈加碼戰略投資紛享銷客,新一輪融資達數億元人民幣。作為企業雲服務領導廠商,金蝶在企業雲服務及平台領域持續佈局,國際權威分析機構IDC最新數據表明,金蝶連續4年在中國企業級ERMSaaS佔有率排名第一。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.